RPG Life Sciences Limited has submitted a regulatory disclosure to the National Stock Exchange of India Limited and BSE Limited regarding the completion of a business acquisition by its wholly-owned subsidiary.
The company informs that its wholly-owned subsidiary, RPG Active Pharma Limited (RPGAP), has completed the acquisition of the Active Pharmaceutical Ingredients (APIs) and intermediates businesses from Raghava Life Sciences Private Limited (RLSPL). The acquisition was executed as a going concern by way of a slump sale, pursuant to a Business Transfer Agreement (BTA) that was previously intimated to the exchanges via a letter dated September 2, 2026.
The transaction has now been formally completed in terms of the BTA. The transfer of the API Business will become effective from September 16, 2026.
The disclosure is made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') for record-keeping purposes. The financial impact of the transaction is not quantified in this disclosure.
The letter is signed by Rajesh Shirambekar, Head – Legal & Company Secretary of RPG Life Sciences Limited, with a digital signature timestamped September 15, 2026, at 23:21:02 +05:30.
#RPG Life Sciences #SEBIDisclosure #Regulation30 #M&A #Pharma #Neutral